Jasper Bos, Ph.D.Managing Director and Senior Vice President at M Ventures
Jasper Bos joined Merck’s previous biopharma fund of M Ventures in 2009 and transitioned to Senior Vice President and Managing Director M Ventures in 2019. At M Ventures, Jasper Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Luendbeck for close to US1,100bn, Calypso Biotech, Inthera, Metabomed and Asceneuron. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute. Jasper published over 35 articles on health economics, vaccines and mathematical modelling.